The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE

Publication: Berlin : Springer Verlag
Original Publication: Berlin : Springer International, c1991-

Biomarkers/*blood ; Diabetes Mellitus, Type 2/*blood ; Diabetes Mellitus, Type 2/*drug therapy ; Oxidative Stress/*drug effects ; Stilbenes/*pharmacology; Adult ; Aged ; Antioxidants/pharmacology ; Biomarkers/analysis ; Body Weight/drug effects ; C-Reactive Protein/metabolism ; Diabetes Mellitus, Type 2/metabolism ; Dietary Supplements ; Double-Blind Method ; Female ; Humans ; Hydrogen Peroxide/blood ; Male ; Malondialdehyde/blood ; Middle Aged ; Placebos ; Protein Carbonylation/drug effects ; Resveratrol

Aims: Oxidative stress plays a pivotal role in the pathogenesis of type 2 diabetes (T2D). In vitro and animal studies have shown that resveratrol exerts an antioxidant effect, but clinical trials addressing this effect in patients with T2D are limited. The aim of this study was to determine whether resveratrol supplementation affects oxidative stress markers in a randomized, placebo-controlled, double-blind clinical trial.
Methods: A total of 48 patients with T2D randomly were assigned to receive 800 mg/day resveratrol or placebo for 2 months. Plasma total antioxidant capacity, malondialdehyde concentration, protein carbonyl and total thiol contents, intracellular superoxide anion (O 2 ^- ·) and hydrogen peroxide (H 2 O 2 ) in PBMCs, the expression of genes involved in oxidative stress responses (Nrf2, SOD, Cat, HO-1, RAGE, NOS) in PBMCs, and metabolic and anthropometric parameters were measured at the baseline and at the trial end.
Results: Compared with the placebo group, resveratrol reduced plasma protein carbonyl content and PBMCs O 2 ^- · level and significantly increased plasma total antioxidant capacity and total thiol content. Furthermore, the expression of Nrf2 and SOD was significantly increased after resveratrol consumption. Resveratrol had no significant effects on the metabolic and anthropometric parameters except for a significant reduction in weight, BMI, and blood pressure levels. Resveratrol was well tolerated, and no serious adverse event was occurred.
Conclusions: Our study demonstrated that 8 weeks of supplementation with 800 mg/day resveratrol has an antioxidant effect in the blood and PBMCs of patients with T2D. Clinical Trial Registry number and website IRCT registration number: IRCT2015072523336N1 and http://en.search.irct.ir/view/24752 .

Comment in: Acta Diabetol. 2018 Jul;55(7):755-756. (PMID: 29796859)
Comment in: Acta Diabetol. 2018 Jul;55(7):757. (PMID: 29796860)
Erratum in: Acta Diabetol. 2018 Oct;55(10):1087. (PMID: 29909463)

94-01-30-28313 Tehran University of Medical Sciences and Health Services; 1393-04-97-1879 Tehran University of Medical Sciences and Health Services

Keywords: Clinical trial; Nrf2; Oxidative stress; PBMC; ROS; Resveratrol; Type 2 diabetes

IRCT IRCT2015072523336N1

0 (Antioxidants)
0 (Biomarkers)
0 (Placebos)
0 (Stilbenes)
4Y8F71G49Q (Malondialdehyde)
9007-41-4 (C-Reactive Protein)
BBX060AN9V (Hydrogen Peroxide)
Q369O8926L (Resveratrol)

Date Created: 20180123 Date Completed: 20180524 Latest Revision: 20181202

20221213

10.1007/s00592-017-1098-3

29357033